Nyxoah reported its second quarter financial and operating results for 2025, with revenue reaching €1.3 million, a 74% increase from the previous year. The FDA approved their Genio® System for the U.S. market, marking a significant milestone for the company. The system offers bilateral hypoglossal neurostimulation therapy, providing a unique solution for OSA patients. The approval was based on the successful DREAM pivotal study data, showcasing the system’s efficacy regardless of the patient’s sleeping position. The company’s financials for the quarter showed a total operating loss of €19.9 million and cash, cash equivalents, and financial assets totaling €43.0 million as of June 30, 2025. The full financial report is available on Nyxoah’s investor page.

Read more at GlobeNewswire: Nyxoah Reports Second Quarter Financial and Operating